Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018
Trevena, Inc. (TRVN)
Last trevena, inc. earnings: 3/12 07:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.trevena.com/investor-relations
Company Research
Source: GlobeNewswire
CHESTERBROOK, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee on October 11, 2018 in Silver Spring, MD, to discuss the safety and efficacy of oliceridine injection for the management of moderate to severe acute pain. The Company‘s New Drug Application (NDA) submission for oliceridine was accepted for review by the FDA on January 2, 2018. The Prescription Drug User Fee Act (PDUFA) target date for completion of review by FDA of November 2, 2018 remains unchanged. “We look forward to the Advisory Committee meeting on October 11 and the opportunity to present our perspectives on the oliceridine clinical data and its potential role in treating moderate to severe acute pain,” said Maxine Gowen, President and Chief Executive Officer. “We remain committed to working closely with the FDA towards achieving the goal of
Show less
Read more
Impact Snapshot
Event Time:
TRVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVN alerts
High impacting Trevena, Inc. news events
Weekly update
A roundup of the hottest topics
TRVN
News
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
TRVN
Earnings
- 8/14/23 - Miss
TRVN
Analyst Actions
- 4/2/24 - HC Wainwright
TRVN
Sec Filings
- 5/3/24 - Form DEFR14A
- 4/29/24 - Form DEF
- 4/22/24 - Form 8-K
- TRVN's page on the SEC website